CompletedNot Applicable

Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis

United States34 participantsStarted 2019-05-01

Plain-language summary

The purpose of this study is to investigate the utility of a continuous glucose monitor device (CGM) in screening for cystic fibrosis related diabetes. The investigators will also study how fat deposition in the pancreas and liver impacts insulin production and response, as measured by a frequently sampled oral glucose tolerance test.

Who can participate

Age range6 Years – 40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Cystic fibrosis confirmed by sweat chloride or genetics * Pancreatic insufficient or pancreatic sufficient * No change in insulin status (either initiating or discontinuing) in the past 3 months Exclusion Criteria: * CF liver disease with portal hypertension * Systemic glucocorticoid exposure the past 2 weeks (does not include inhaled) * Current pulmonary exacerbation treated with antibiotics * Baseline or current FEV1 \<30% at time of recruitment * Transplant recipient * Pancreatic sufficient on insulin * Started CFTR modulator in the past 3 months

What they're measuring

Glycemic agreement between plasma glucose and CGM

Timeframe: 0 min-120min

Pancreatic Fat and Glycemic measures

Timeframe: 0min-120min

Trial details

NCT IDNCT03961516

SponsorUniversity Hospitals Cleveland Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-08-30

View on ClinicalTrials.gov More Cystic Fibrosis trials